NasdaqCM - Delayed Quote USD

Adial Pharmaceuticals, Inc. (ADIL)

1.4200 -0.0200 (-1.39%)
At close: May 15 at 4:00 PM EDT
1.4200 0.00 (0.00%)
After hours: May 15 at 5:30 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
6,887.9470
--
10,859.4750
17,740.3260
10,927.9850
Operating Income
-6,887.9470
--
-10,859.4750
-17,740.3260
-10,927.9850
Net Non Operating Interest Income Expense
69.7790
--
63.3380
6.5390
32.4950
Other Income Expense
-183.7220
--
522.0000
-1,783.6160
2.5000
Pretax Income
-7,001.8900
--
-10,796.1370
-19,517.4030
-10,892.9900
Tax Provision
--
--
--
-94.0770
--
Net Income Common Stockholders
-5,123.3410
--
-12,731.4160
-19,423.3260
-10,892.9900
Diluted NI Available to Com Stockholders
-5,123.3410
--
-12,731.4160
-19,423.3260
-10,892.9900
Basic EPS
-3.60
-3.60
-12.71
-26.00
-21.75
Diluted EPS
-3.60
-3.60
-12.71
-26.00
-21.75
Basic Average Shares
1,424.6610
1,424.6610
1,001.5050
743.5490
498.5250
Diluted Average Shares
1,424.6610
1,424.6610
1,001.5050
743.5490
498.5250
Total Operating Income as Reported
-6,887.9470
--
-10,859.4750
-19,288.7230
-10,927.9850
Total Expenses
6,887.9470
--
10,859.4750
17,740.3260
10,927.9850
Net Income from Continuing & Discontinued Operation
-5,123.3410
--
-12,731.4160
-19,423.3260
-10,892.9900
Normalized Income
-7,001.8900
--
-10,796.1370
-17,602.0005
-10,892.9900
Interest Income
69.7790
--
63.3380
6.5390
32.4950
Net Interest Income
69.7790
--
63.3380
6.5390
32.4950
EBIT
-6,887.9470
--
-10,859.4750
-17,740.3260
-10,927.9850
EBITDA
-6,887.3830
--
-10,858.9110
-17,685.2200
-10,927.4210
Reconciled Depreciation
0.5640
--
0.5640
55.1060
0.5640
Net Income from Continuing Operation Net Minority Interest
-7,001.8900
--
-10,796.1370
-19,423.3260
-10,892.9900
Total Unusual Items Excluding Goodwill
522.0000
--
522.0000
-1,830.1100
--
Total Unusual Items
522.0000
--
522.0000
-1,830.1100
--
Normalized EBITDA
-6,887.3830
--
-10,858.9110
-15,855.1100
-10,927.4210
Tax Rate for Calcs
--
--
--
0.0000
--
Tax Effect of Unusual Items
--
--
--
-8.7845
--
12/31/2020 - 7/27/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NKGN NKGen Biotech, Inc.
1.1400
0.00%
 
BDRX Biodexa Pharmaceuticals Plc
1.1300
+2.73%
 
LGVN Longeveron Inc.
1.3400
-3.60%
 
RLYB Rallybio Corporation
1.9100
+3.80%
 
CYCC Cyclacel Pharmaceuticals, Inc.
2.4400
-14.08%
 
CMND Clearmind Medicine Inc.
1.2800
-0.78%
 
ALLR Allarity Therapeutics, Inc.
0.6801
-13.75%
 
TCBP TC Biopharm (Holdings) Plc
1.1200
-2.61%
 
PALI Palisade Bio, Inc.
6.38
+2.24%
 
BPTH Bio-Path Holdings, Inc.
2.2400
-13.18%